<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096083</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000391827</org_study_id>
    <secondary_id>NCI-04-C-0273</secondary_id>
    <secondary_id>NCI-6332</secondary_id>
    <secondary_id>DELCATH-G990039</secondary_id>
    <nct_id>NCT00096083</nct_id>
    <nct_alias>NCT00091455</nct_alias>
  </id_info>
  <brief_title>Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer</brief_title>
  <official_title>A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delcath Systems Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Delcath Systems Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances&#xD;
      directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different&#xD;
      ways may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving an hepatic arterial infusion of&#xD;
      melphalan together with hepatic perfusion works in treating patients with unresectable liver&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate and duration of response in patients with unresectable&#xD;
           primary or metastatic liver cancer treated with intrahepatic arterial infusion of&#xD;
           melphalan with venous filtration via peripheral hepatic perfusion.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the patterns of recurrence in patients treated with this regimen.&#xD;
&#xD;
        -  Determine progression-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Evaluate the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Assess the filter characteristics including melphalan pharmacokinetics and filtration of&#xD;
           cytokines and clotting factors during and after treatment.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to primary tumor histology (neuroendocrine tumor&#xD;
      vs primary hepatic malignancy vs adenocarcinoma of gastrointestinal or other origin).&#xD;
&#xD;
      Patients undergo peripheral isolated hepatic perfusion in which a catheter is placed via the&#xD;
      groin into the hepatic artery and another into the hepatic vein. Patients then receive&#xD;
      melphalan as an intrahepatic arterial infusion over 15-30 minutes. Treatment repeats&#xD;
      approximately every 3-8 weeks for up to 6 total infusions in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 4 months for 1 year, and then&#xD;
      periodically thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 105 patients will be accrued for this study within 4-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignancies</measure>
    <time_frame>Survivial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the patterns of recurrence following percutaneous hepatic perfusions (PHP) with melphalan</measure>
    <time_frame>Survival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the progression free and overall survival in patients with hepatic malignancies following this therapy</measure>
    <time_frame>Survivial</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Melphalan Administration PHP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
    <arm_group_label>Melphalan Administration PHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>Melphalan Administration PHP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed hepatic malignancy&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
               -  Disease predominantly in the parenchyma of the liver&#xD;
&#xD;
               -  One of the following primary tumor histologies:&#xD;
&#xD;
                    -  Adenocarcinoma of gastrointestinal or other origin&#xD;
&#xD;
                    -  Neuroendocrine tumor (except gastrinoma)&#xD;
&#xD;
                    -  Primary hepatic malignancy (e.g., hepatocellular cancer or intra-hepatic&#xD;
                       cholangiocarcinoma)&#xD;
&#xD;
                    -  Cutaneous or ocular melanoma (patients must have received prior regional&#xD;
                       melphalan therapy)&#xD;
&#xD;
               -  Hepatic metastases from colorectal tumors allowed provided patient has undergone&#xD;
                  prior first-line chemotherapy, including irinotecan or oxaliplatin&#xD;
&#xD;
          -  Limited unresectable extrahepatic disease on preoperative radiological studies allowed&#xD;
             if life-limiting component of progressive disease is in the liver&#xD;
&#xD;
               -  Limited extrahepatic disease includes, but is not limited to, the following:&#xD;
&#xD;
                    -  Up to 4 pulmonary nodules each &lt; 1 cm in diameter&#xD;
&#xD;
                    -  Retroperitoneal lymph nodes each &lt; 3 cm in diameter&#xD;
&#xD;
                    -  Less than 10 skin or subcutaneous metastases each &lt; 1 cm in diameter&#xD;
&#xD;
                    -  Asymptomatic bone metastases that have been or could be palliatively treated&#xD;
                       with external beam radiotherapy&#xD;
&#xD;
                    -  Resectable solitary metastasis to any site&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Hematocrit &gt; 27%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,300/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  PT ≤ 2 seconds of upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 10 times ULN&#xD;
&#xD;
          -  No Childs class B or C cirrhosis&#xD;
&#xD;
          -  No portal hypertension by history, endoscopy, or radiologic studies&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  LVEF ≥ 40%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
          -  FEV_1 ≥ 30% of predicted&#xD;
&#xD;
          -  DLCO ≥ 40% of predicted&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No severe allergic reaction to iodine contrast agent that is not controlled by&#xD;
             premedication with antihistamines or steroids&#xD;
&#xD;
          -  No known hypersensitivity reaction to melphalan or heparin in the presence of a&#xD;
             heparin induced thrombocytopenia (HIT) antibody&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Weight &gt; 35 kg&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No documented latex allergy&#xD;
&#xD;
          -  No evidence of intracranial abnormalities which would lead to risk for bleeding with&#xD;
             anticoagulation (e.g., stroke or active metastasis)&#xD;
&#xD;
          -  No evidence of active ulcer disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 1 month since prior biologic therapy and recovered&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 1 month since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Premenopausal women (i.e., have had a period within the past 12 months) must be&#xD;
             willing to undergo hormonal suppression during study treatment&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 1 month since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior Whipple resection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior intrahepatic perfusion (with or without arterial infusion with floxuridine) or&#xD;
             peripheral hepatic perfusion allowed provided the patient had a radiographic partial&#xD;
             response of 3 months' duration after therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
&#xD;
          -  No concurrent chronic anticoagulation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marybeth Hughes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>October 22, 2013</last_update_submitted>
  <last_update_submitted_qc>October 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>liver metastases</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the extrahepatic bile duct</keyword>
  <keyword>adenocarcinoma of the gallbladder</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>carcinoma of the appendix</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>recurrent islet cell carcinoma</keyword>
  <keyword>recurrent pheochromocytoma</keyword>
  <keyword>metastatic pheochromocytoma</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>insulinoma</keyword>
  <keyword>WDHA syndrome</keyword>
  <keyword>glucagonoma</keyword>
  <keyword>pancreatic polypeptide tumor</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>intraocular melanoma</keyword>
  <keyword>conjunctival melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

